Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 236.00 | |
10 mg | In stock | $ 346.00 | |
25 mg | In stock | $ 581.00 | |
50 mg | In stock | $ 829.00 | |
100 mg | In stock | $ 1,150.00 | |
500 mg | In stock | $ 2,280.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 273.00 |
Description | PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1. |
In vitro | PD 198306 (10 μM) reduces Tha-Crimson replication by 30% at 18 h and 50% at 36 h. PD 198306 (10 μM) significantly inhibits Tha-GFP replication by 25%[1]. |
In vivo | In male Sprague Dawley rats bearing neuropathic pain, PD 198306 (1-30 μg/10 μL; i.t.) dose-dependently blocks static allodynia in both the chronic constriction injury and the streptozocin models[2]. |
Molecular Weight | 476.23 |
Formula | C18H16F3IN2O2 |
CAS No. | 212631-61-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (94.49 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD 198306 212631-61-3 MAPK MEK inhibit neuropathic Inhibitor MAP2K rabies mitogen-activated protein drug MAPKK phosphatases inositol RNA pain PD198306 interference ERK antihyperalgesic screening Mitogen-activated protein kinase kinase phosphate kinases PD-198306 inhibitor